{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017704","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.079014+00:00","generated_at":"2026-05-22T07:22:42.032622+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback","bullets":["Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).","FY2025 revenue guidance raised to >$500M; FY2026 to >$625M; adjusted EBITDA guidance >$235M and >$340M, respectively.","Board authorized $500M share repurchase program (~8% of market cap); timing and amount discretionary.","Debt reorganized: $30M borrowed on revolver to repay term loan; revolver outstanding $72.5M, term loan $2.5M; cost of debt down 1.1%.","FDA-approved yield enhancement process expected to increase IG output 20% from same plasma volume, supporting future growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017704","json":"https://secwatch.observer/filing/0001140361-25-017704.json","markdown":"https://secwatch.observer/filing/0001140361-25-017704.md","text":"https://secwatch.observer/filing/0001140361-25-017704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/0001140361-25-017704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036125017704/ef20048524_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:22:42.032622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}